CN101890021A - Cefozopran hydrochloride for injection and preparation method thereof - Google Patents
Cefozopran hydrochloride for injection and preparation method thereof Download PDFInfo
- Publication number
- CN101890021A CN101890021A CN 201010236297 CN201010236297A CN101890021A CN 101890021 A CN101890021 A CN 101890021A CN 201010236297 CN201010236297 CN 201010236297 CN 201010236297 A CN201010236297 A CN 201010236297A CN 101890021 A CN101890021 A CN 101890021A
- Authority
- CN
- China
- Prior art keywords
- injection
- cefozopran hydrochloride
- cefozopran
- preparation
- hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the field of medical preparations, and relates to cefozopran hydrochloride for injection and a preparation method thereof. The cefozopran hydrochloride for injection comprises the following components in part by weight: 200 to 1,000 parts of cefozopran hydrochloride, 350 to 2,000 parts of soybean lecithin, 150 to 450 parts of cholesterol, 45 to 100 parts of anhydrous sodium carbonate and 25 to 85 parts of glucose. The cefozopran hydrochloride for injection can achieve better treatment effect on the basis of low content of a main ingredient, and simultaneously reduces the incidence rate of untoward effect, so the product is more safe and effective.
Description
Technical field
The invention belongs to field of medicine preparations, relate to a kind of cefozopran hydrochloride for injection and preparation method thereof.
Background technology
Cefozopran hydrochloride (cefozopran hydrochloride) be the research and development of Japanese military field pharmaceutical industries company the 4th generation cephalosporin for injections, be widely used in comprising that as the choice drug at community infection initial stage each section of infection of newborn infects the treatment of disease in Japan at present.Except MRSA, it has broad spectrum of activity, to the activity of gram positive bacteria be better than ceftazidime generally, cephalo adjoins oxime and flomoxef, and is and suitable with cefpirome, and gram-negative bacteria and above-mentioned contrast medical instrument are had equal activity.It has the stability of height to beta-lactamase, and widely distributed in the body, blood plasma and tissue concentration are higher, and is most of with former medicine form drainage .24h homaluria rate 80%～90% from urine, no body accumulation tendency.
The chemical formula of cefozopran hydrochloride is 1-[[(6R, 7R)-7-[(Z)-2-(5-amino-1,2,4-thiadiazoles-3-yl)-2-methoxyimino acetamido]-2-carboxyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-3-yl] methyl] imidazo [1,2-b] pyridazine inner salt hydrochlorate, its chemical structural formula is as follows:
Cefozopran hydrochloride belong to the 4th generation cephalosporin for injections, it is synthetic at first in 1985 by 13 military field pharmaceutical industries companies, and applied for the chemical compound patent of invention, subsequently it has been carried out pharmacodynamics, pharmacological toxicology, pharmacokinetics and the clinical research of the system of going deep into.Submitted application for quotation in 1993 to 13 Health and human services departments, obtain the listing permission of 13 Health and human services departments June nineteen ninety-five, begin August in the same year 13 listings, commodity are called Firstcin.13 nineteen ninety-fives go on the market then that crude drug output promptly reaches 708 tons, about 2,300,000,000 13 yuan of preparation sales volume.World's sales volume of this product in 1997 is 0.74 hundred million dollar, rises 7.1% than 1996.The relevant expert estimates about 20,000,000,000 yen of 13 sales volume peak value.This product has been recorded in 13 officina sides the 14 edition.At present this product has been widely used as the choice drug at community infection initial stage at 13.The cefozopran hydrochloride for injection of Japan listing, principal agent is non-sterile bulk drug, need add during the preparation injection sodium carbonate become behind the sodium salt lyophilizing cefozopran hydrochloride.
Chinese patent application CN101265267A (open day 2008 on JIUYUE 17) discloses a kind of preparation method of cefozopran hydrochloride and cefozopran hydrochloride injectable powder and preparation method thereof.This invention is by obtaining injectable powder with the cefozopran hydrochloride crystal of 500-1000 weight portion, the natrium carbonicum calcinatum of 103-206 weight portion and the sodium chloride mixing packing of 60-120 weight portion.Yet, utilize the cefozopran hydrochloride injectable powder of this prescription and prepared to need per injection 1000mg principal agent just can reach therapeutic effect, this has increased this medicine incidence rate of adverse reaction indirectly.
Summary of the invention
First purpose of the present invention is to overcome the deficiency that existing technology exists, a kind of cefozopran hydrochloride for injection Liposomal formulation is provided, it can reach on the basis that the low dosage cefozopran hydrochloride uses and the normal injection identical curative effect of cefozopran, reduce incidence rate of adverse reaction simultaneously, made product more safe and effective.
Cefozopran hydrochloride for injection Liposomal formulation of the present invention is made up of cefozopran hydrochloride, soybean lecithin, cholesterol, natrium carbonicum calcinatum and the glucose of recipe quantity, calculates by weight, and the content that each component is concrete is as follows:
Cefozopran hydrochloride 200-1000 part
Soybean lecithin 350-2000 part
Cholesterol 150-450 part
Natrium carbonicum calcinatum 45-100 part
Glucose 25-85 part
Preferably, cefozopran hydrochloride for injection Liposomal formulation of the present invention calculates by weight, and the content that each component is concrete is as follows:
Cefozopran hydrochloride 250-500 part
Soybean lecithin 450-1200 part
Cholesterol 300-400 part
Natrium carbonicum calcinatum 60-80 part
Glucose 50-65 part
In a preferred embodiment of the present invention, calculate by weight, the concrete content of each component of described cefozopran hydrochloride for injection Liposomal formulation is as follows:
Cefozopran hydrochloride 500g
Soybean lecithin 800g
Cholesterol 350g
Natrium carbonicum calcinatum 65g
Glucose 60g
Second purpose of the present invention provides the preparation method of above-mentioned cefozopran hydrochloride for injection Liposomal formulation, comprises the steps:
1) takes by weighing soybean lecithin, the cholesterol of recipe quantity, make its dissolving, mix homogeneously with dehydrated alcohol;
2) with 1) liposome liquid of step preparation places on the thin cured vaporizer, and ethanol is removed in decompression, the preparation immobilized artificial membrane;
3) be that 4.8 citric acid-sodium citrate buffer immerses immobilized artificial membrane with an amount of pH, after treating the complete aquation of phospholipid, prepare liposome with high pressure homogenizer, after checking that the liposome particle diameter is qualified, the filtering with microporous membrane degerming, measure the phospholipid amount with the blue method of molybdenum, transfer to the phospholipid amount with sterilized water and be not less than 30mg/ml;
4) by prescription configuration 0.3mol/L, pH is 11.4 Carbon Dioxide sodium solution, and is standby after the micro-pore-film filtration degerming;
5) take by weighing the cefozopran hydrochloride of recipe quantity, be dissolved in water for injection, after the filtering with microporous membrane degerming, place 50 ℃ of water-baths to be incubated;
6) sodium carbonate liquor with the step 4) preparation mixes with the liposome of step 3) preparation, obtains liposome turbid liquor, adds then in the cefozopran hydrochloride solution of preheating, then adds the glucose of recipe quantity;
7) mixed liquor with the step 6) preparation places 50 ℃ of water-baths to be incubated 10min, and jolting frequently, and packing after the assay was approved, lyophilizing are promptly.
The present invention has following beyond thought technique effect with respect to prior art:
1) research of the pharmacodynamic experiment by the pneumonia of rats model draws, and two dosage groups of cefozopran hydrochloride for injection Liposomal formulation are compared with model control group, have utmost point significant difference (
*P＜0.01), this illustrates that cefozopran hydrochloride for injection of the present invention has good therapeutical effect to pneumonia of rats.Cefozopran hydrochloride for injection Liposomal formulation low dose group is suitable with powder pin matched group in treatment pneumonia of rats curative effect, cefozopran hydrochloride for injection Liposomal formulation high dose group is better than contrasting powder pin group in the curative effect of treatment pneumonia of rats, and the two has significant difference (#P＜0.05), after this explanation is prepared into liposome with cefozopran hydrochloride, can reach the curative effect of the regular hydrochloric acid cefozopran of heavy dose with the cefozopran hydrochloride Liposomal formulation of low dose, reduced the consumption of cefozopran hydrochloride, reduce the untoward reaction of medicine, improved security of products.
2) show that by the animal safety result of the test cefozopran hydrochloride for injection Liposomal formulation of the present invention does not have the obvious stimulation effect through the administration of rabbit auricular vein to rabbit blood vessel and muscle; Intravenous administration does not have sensitization to Cavia porcellus; Tame rabbit erythrocyte is not had external haemolysis and causes about coagulation, illustrated that injection cefozopran of the present invention is safe and reliable, meet the injection requirement.Cefozopran hydrochloride for injection Liposomal formulation of the present invention is to the influence of pneumonia of rats model
1. animal and grouping
48 of healthy male SPF level SD rats, body weight 180～200g gives SPF level animal standard feed, freely fetches water.Rat is divided into 4 groups at random with the table of random number method, is respectively model control group, powder pin matched group, liposome low dose group, liposome high dose group, 12 every group.Each organizes the equal not statistically significant of ratio difference of body weight, basal body temperature, total white blood cells and neutrophilic granulocyte.
2. the preparation of bacteria suspension
Be inoculated on the MH culture medium after the frozen Klebsiella Pneumoniae recovery, 37 ℃ of constant temperature incubator incubated overnight 24h adopt Maxwell standard pipe nephelometer number, are made into 2 Maxwell concentration units (6 * 10CFU/ml) with aseptic double-distilled water.
3. set up the pneumonia model
Press 300mg/kg body weight intraperitoneal injection of anesthesia rat with chloral hydrate, the reuse syringe slowly drips people rat intranasal with the bacteria suspension of above-mentioned preparation, left side nose keeps the low and left lateral position 10min of head height foot after splashing into 0.1ml, right again nose keeps the low and right arm reclining 10min of head height foot after splashing into 0.1ml, makes bacterium liquid be uniformly distributed in two lungs.
4. anti-mattress Drug therapy
Antibacterials dosage is as follows respectively:
Model control group: with 0.9% normal saline of volume
Powder pin matched group: the cefozopran hydrochloride of 100mg/kg (giving cefozopran hydrochloride injectable powder) by Chinese patent application CN101265267A embodiment 2 preparations
The cefozopran hydrochloride of liposome low dose group: 50mg/kg (giving the cefozopran hydrochloride for injection Liposomal formulation of the embodiment of the invention 1 preparation)
The cefozopran hydrochloride of liposome high dose group: 100mg/kg (giving the cefozopran hydrochloride for injection Liposomal formulation of the embodiment of the invention 2 preparations)
Each group all adopts intramuscular injection, and 1 time/12h, begin treatment behind inoculated bacteria 24h is 72h the course of treatment.
5. observation index
4h after last 1 administration, rat is put to death with the cervical vertebra dislocation method, open the thoracic cavity rapidly and isolate right lung, put into tissue grinder, grind to form lung tissue homogenate, add the 1ml sterile saline and make tissue suspension, do 10 times of serial dilutions to 1000 times again, get each dilution factor specimen 10 μ l and be inoculated in blood agar plate, incubated overnight 24h in 37 ℃ of incubators, carry out colony counting, what colony-forming units (CFU/g) are arranged in the conversion lung tissue.CFU number=clump count * extension rate * 100 in each right lung tissue.
Each organizes lung tissue of rats homogenate colony counting, the results are shown in Table 1.
Table 1 is respectively organized lung tissue homogenate colony counting
Compare with model control group,
*P＜0.05,
*P＜0.01
Compare #P＜0.05 with powder pin matched group
Conclusion: two dosage groups of cefozopran hydrochloride for injection Liposomal formulation are compared with model control group, have utmost point significant difference (
*P＜0.01), this illustrates that cefozopran hydrochloride for injection of the present invention has good therapeutical effect to pneumonia of rats.Cefozopran hydrochloride for injection Liposomal formulation low dose group is suitable with powder pin matched group in treatment pneumonia of rats curative effect, cefozopran hydrochloride for injection Liposomal formulation high dose group is better than contrasting powder pin group in the curative effect of treatment pneumonia of rats, and the two has significant difference (#P＜0.05), after this explanation is prepared into liposome with cefozopran hydrochloride, can reach the curative effect of the regular hydrochloric acid cefozopran of heavy dose with the cefozopran hydrochloride Liposomal formulation of low dose, reduced the consumption of cefozopran hydrochloride, reduce the untoward reaction of medicine, improved security of products.
The safety testing of cefozopran hydrochloride for injection Liposomal formulation of the present invention
With the injection cefozopran Liposomal formulation of embodiment 1 preparation, test by " chemicals zest, anaphylaxis and hemolytic investigative technique guideline ":
(1) 0.5ml/ sensitization of injection cefozopran normal saline solution (60mg/ml) of intramuscular injection embodiment 1 preparation the next day that Cavia porcellus being distinguished every, totally 3 times, injection cefozopran normal saline solution (120mg/ml) 0.5ml/ that every single dose intravenous injection embodiment of the 14th and 21 day difference 1 prepares after the sensitization only first, after attacking, symptoms of allergic such as perpendicular hair, dyspnea, sneeze, death do not appear in Cavia porcellus.
(2) the injection cefozopran when clinical maximum administration concentration (200mg/ml) to red letter no haemolysis of newspaper of rabbit and agglutination.
(3) the normal saline diluent (150mg/ml, 2ml/kg, 1 time/day) of continuous 5 days slow injection injection usefulness cefozoprans of rabbit auricular vein, perusal blood vessel no abnormality seen changes; The result of histopathologic examination shows that administration group auricular vein blood vessel and surrounding tissue and matched group be no significant difference relatively.
The result shows that cefozopran hydrochloride for injection Liposomal formulation of the present invention does not have the obvious stimulation effect through the administration of rabbit auricular vein to rabbit blood vessel and muscle; Intravenous administration does not have sensitization to the liver Mus; Tame rabbit erythrocyte is not had external haemolysis and causes about coagulation, illustrated that injection cefozopran of the present invention is safe and reliable, meet the injection requirement.
The specific embodiment
It will be appreciated that; for those skilled in the art; in enforcement of the present invention, clearly and can be easy to make and do not deviate from other embodiment and the modification of the scope and the aim of the invention described above, all be included among protection scope of the present invention.Therefore, the scope that should not be construed as claims is limited in following examples.
The preparation of embodiment 1 cefozopran hydrochloride for injection
Prescription:
Cefozopran hydrochloride 500g
Soybean lecithin 800g
Cholesterol 350g
Natrium carbonicum calcinatum 65g
Glucose 60g
Preparation technology:
1) takes by weighing soybean lecithin, the cholesterol of recipe quantity, make its dissolving, mix homogeneously with dehydrated alcohol;
2) with 1) liposome liquid of step preparation places on the thin cured vaporizer, and ethanol is removed in decompression, the preparation immobilized artificial membrane;
3) be that 4.8 citric acid-sodium citrate buffer immerses immobilized artificial membrane with an amount of pH, after treating the complete aquation of phospholipid, prepare liposome with high pressure homogenizer, after checking that the liposome particle diameter is qualified, the filtering with microporous membrane degerming, measure the phospholipid amount with the blue method of molybdenum, transfer to the phospholipid amount with sterilized water and be not less than 30mg/ml;
4) by prescription configuration 0.3mol/L, pH is 11.4 Carbon Dioxide sodium solution, and is standby after the micro-pore-film filtration degerming;
5) take by weighing the cefozopran hydrochloride of recipe quantity, be dissolved in water for injection, after the filtering with microporous membrane degerming, place 50 ℃ of water-baths to be incubated;
6) sodium carbonate liquor with the step 4) preparation mixes with the liposome of step 3) preparation, obtains liposome turbid liquor, adds then in the cefozopran hydrochloride solution of preheating, then adds the glucose of recipe quantity;
7) mixed liquor with the step 6) preparation places 50 ℃ of water-baths to be incubated 10min, and jolting frequently, and packing after the assay was approved, lyophilizing are promptly.
The preparation of embodiment 2 cefozopran hydrochloride for injection
Prescription:
Cefozopran hydrochloride 1000g
Soybean lecithin 2000g
Cholesterol 400g
Natrium carbonicum calcinatum 100g
Glucose 80g
Preparation technology: with embodiment 1
The preparation of embodiment 3 cefozopran hydrochloride for injection
Prescription:
Cefozopran hydrochloride 200g
Soybean lecithin 425g
Soybean lecithin 800g
Cholesterol 350g
Natrium carbonicum calcinatum 65g
Glucose 60g
Preparation technology:
1) takes by weighing soybean lecithin, the cholesterol of recipe quantity, make its dissolving, mix homogeneously with dehydrated alcohol;
2) with 1) liposome liquid of step preparation places on the thin cured vaporizer, and ethanol is removed in decompression, the preparation immobilized artificial membrane;
3) be that 4.8 citric acid-sodium citrate buffer immerses immobilized artificial membrane with an amount of pH, after treating the complete aquation of phospholipid, prepare liposome with high pressure homogenizer, after checking that the liposome particle diameter is qualified, the filtering with microporous membrane degerming, measure the phospholipid amount with the blue method of molybdenum, transfer to the phospholipid amount with sterilized water and be not less than 30mg/ml;
4) by prescription configuration 0.3mol/L, pH is 11.4 Carbon Dioxide sodium solution, and is standby after the micro-pore-film filtration degerming;
5) take by weighing the cefozopran hydrochloride of recipe quantity, be dissolved in water for injection, after the filtering with microporous membrane degerming, place 50 ℃ of water-baths to be incubated;
6) sodium carbonate liquor with the step 4) preparation mixes with the liposome of step 3) preparation, obtains liposome turbid liquor, adds then in the cefozopran hydrochloride solution of preheating, then adds the glucose of recipe quantity;
7) mixed liquor with the step 6) preparation places 50 ℃ of water-baths to be incubated 10min, and jolting frequently, and packing after the assay was approved, lyophilizing are promptly.
The preparation of embodiment 2 cefozopran hydrochloride for injection
Prescription:
Cefozopran hydrochloride 1000g
Soybean lecithin 2000g
Cholesterol 400g
Natrium carbonicum calcinatum 100g
Glucose 80g
Preparation technology: with embodiment 1
The preparation of embodiment 3 cefozopran hydrochloride for injection
Prescription:
Cefozopran hydrochloride 200g
Soybean lecithin 425g
The preparation of embodiment 7 cefozopran hydrochloride for injection
Prescription:
Cefozopran hydrochloride 400g
Soybean lecithin 1000g
Cholesterol 280g
Natrium carbonicum calcinatum 50g
Glucose 85g
Preparation technology: with embodiment 1
The preparation of embodiment 8 cefozopran hydrochloride for injection
Prescription:
Cefozopran hydrochloride 500g
Soybean lecithin 1200g
Cholesterol 350g
Natrium carbonicum calcinatum 80g
Glucose 65g
Preparation technology: with embodiment 1
Claims (3)
1. cefozopran hydrochloride for injection is characterized in that: calculate by weight, the concrete content of each component of described cefozopran hydrochloride for injection is as follows:
Cefozopran hydrochloride 200-1000 part
Soybean lecithin 350-2000 part
Cholesterol 150-450 part
Natrium carbonicum calcinatum 45-100 part
Glucose 25-85 part.
2. cefozopran hydrochloride for injection as claimed in claim 1 is characterized in that: calculate by weight, the content that each component is concrete is as follows:
Cefozopran hydrochloride 250-500 part
Soybean lecithin 450-1200 part
Cholesterol 300-400 part
Natrium carbonicum calcinatum 60-80 part
Glucose 50-65 part.
3. cefozopran hydrochloride for injection as claimed in claim 1 is characterized in that: juice is calculated by weight, and the content that each component is concrete is as follows:
Cefozopran hydrochloride 500g
Soybean lecithin 800g
Cholesterol 350g
Natrium carbonicum calcinatum 65g
Glucose 60g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010236297 CN101890021A (en) | 2010-07-26 | 2010-07-26 | Cefozopran hydrochloride for injection and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010236297 CN101890021A (en) | 2010-07-26 | 2010-07-26 | Cefozopran hydrochloride for injection and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101890021A true CN101890021A (en) | 2010-11-24 |
Family
ID=43099480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010236297 Pending CN101890021A (en) | 2010-07-26 | 2010-07-26 | Cefozopran hydrochloride for injection and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101890021A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102512375A (en) * | 2012-01-17 | 2012-06-27 | 山东罗欣药业股份有限公司 | Powder injection of cefozopran hydrochloride composition for injection |
| CN102697742A (en) * | 2012-07-06 | 2012-10-03 | 海南海灵化学制药有限公司 | Preparation process of cefozopran hydrochloride for injection |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101265267A (en) * | 2008-02-04 | 2008-09-17 | 山东罗欣药业股份有限公司 | Method for preparing cefozopran hydrochloride, cefozopran hydrochloride powder injection and preparation method thereof |
| CN101444514A (en) * | 2008-12-29 | 2009-06-03 | 海南瑞基药物研究有限公司 | Cefmenoxime hydrochloride preparation for injection and preparation method thereof |
-
2010
- 2010-07-26 CN CN 201010236297 patent/CN101890021A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101265267A (en) * | 2008-02-04 | 2008-09-17 | 山东罗欣药业股份有限公司 | Method for preparing cefozopran hydrochloride, cefozopran hydrochloride powder injection and preparation method thereof |
| CN101444514A (en) * | 2008-12-29 | 2009-06-03 | 海南瑞基药物研究有限公司 | Cefmenoxime hydrochloride preparation for injection and preparation method thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102512375A (en) * | 2012-01-17 | 2012-06-27 | 山东罗欣药业股份有限公司 | Powder injection of cefozopran hydrochloride composition for injection |
| CN102697742A (en) * | 2012-07-06 | 2012-10-03 | 海南海灵化学制药有限公司 | Preparation process of cefozopran hydrochloride for injection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103961364A (en) | Medicine composition containing multiple vitamins as well as preparation method and detection method of medicine composition | |
| CN104302291A (en) | Formulations of bendamustine | |
| CN109432123B (en) | Compound electrolyte glucose injection and preparation method thereof | |
| CN102138919A (en) | New application of sodium ferrous chlorophyll to promotion of erythropoiesis | |
| CN107417556A (en) | L aspartase calciums and preparation method thereof | |
| CN101890021A (en) | Cefozopran hydrochloride for injection and preparation method thereof | |
| CN102145164B (en) | IAPP (Islet Amyloid Polypeptide) analog injection with better stability | |
| CN104013629A (en) | Composite pharmaceutical composition of cefoperazone sodium and tazobactam sodium and preparation process thereof | |
| CN102145162B (en) | Injection of medicine for treating premature delivery | |
| CN102512379A (en) | Novel Echinocandin antifungal pharmaceutical composition and preparation method thereof | |
| CN105769756B (en) | A kind of fumaric acid Sitafloxacin hydrate injection and preparation method thereof | |
| CN111265477B (en) | Carbazochrome sodium sulfonate and sodium chloride injection and preparation method thereof | |
| CN105796565A (en) | Ferrous fumarate folic acid solid preparation and preparation method thereof | |
| CN100560068C (en) | The preparation method of Levogyration sulpiride injection and its | |
| Sharma et al. | Evaluation of mannitol as an osmotherapeutic agent in traumatic brain injuries by measuring serum osmolality | |
| CN109432106B (en) | Compound sulfachlorpyridazine and preparation method thereof | |
| CN105998055A (en) | Injection containing sodium ascorbate and preparing method thereof | |
| CN101879171A (en) | Oral liquid preventing and curing gallinaceous leucocyto zoonosis and preparation method thereof | |
| CN105520955A (en) | Ferric carboxymaltose pharmaceutical composition and preparation method thereof | |
| CN114831935B (en) | Sterile 20 (S) -PPD oral liquid preparation capable of being administrated by nasal feeding and preparation method and application thereof | |
| CN104688823B (en) | Antipruritic Chinese medicine composition of a kind of anti-inflammation and preparation method thereof | |
| CN109470788A (en) | A kind of method of quality control of FUKE QIANJIN PIAN | |
| CN102440968A (en) | More stable desmopressin (DDAVP) polypeptide drug freeze-dried powder injection | |
| CN102727429B (en) | Pidotimod injection with modified stability, and preparation method thereof | |
| Tajali et al. | RBC Transfusion in premature neonates in Mofid Children Hospital 2017 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20101124 |